Genetic Markers, Cancer Biology, and Genetic Diseases: Study Guide

Study Guide - Smart Notes

Tailored notes based on your materials, expanded with key definitions, examples, and context.

Genetic Markers & Disease Discovery

Genome-Wide Association Studies (GWAS) and SNPs

Genome-wide association studies (GWAS) are powerful tools for identifying genetic variants associated with diseases across populations. Single nucleotide polymorphisms (SNPs) serve as genetic markers in these studies, enabling researchers to map disease risk to specific genomic regions.

GWAS: A method that scans the genome for SNPs that occur more frequently in individuals with a particular disease than in those without.
SNPs: Single base-pair variations in the DNA sequence; act as markers for genetic association studies.
Interpretation: GWAS often identifies multiple genes due to the complex, polygenic nature of most diseases.
Example: CYP2C9 gene variants affect drug metabolism rates, influencing drug efficacy and toxicity.

Clinical Translation: Genetic data from GWAS can inform risk prediction, early detection, and therapy selection, forming the basis of precision medicine.

Pharmacogenomics: The study of how genetic variation affects drug response.
Population Differences: Genetic variants can differ in frequency between populations, affecting disease risk and drug response.

Ethical & Scientific Limitations:

Missing Heritability: Not all genetic risk is explained by identified variants.
Gene-Environment Interactions: Environmental factors can modify genetic risk.
Population Bias: GWAS may not be generalizable if study populations lack diversity.
Privacy: Genetic data raises concerns about discrimination and confidentiality.

Gene Therapy

Mechanisms and Delivery

Gene therapy involves introducing functional genes into a patient's cells to treat or prevent disease. Success depends on the disease being caused by a single gene, knowing the defective allele, and having an effective delivery method.

Viral Vectors: Engineered viruses deliver therapeutic genes to target cells. Risks include immune responses and insertional mutagenesis.
Ex vivo Therapy: Cells are modified outside the body and then reintroduced, allowing greater control.
In vivo Therapy: Genes are delivered directly into the patient, which is less invasive but harder to control.

Requirement: Expression must be tissue-specific and regulated to avoid adverse effects.

Gene Editing (CRISPR-Cas9)

Mechanism and Applications

CRISPR-Cas9 is a revolutionary gene editing technology that allows precise modification of DNA sequences within living cells.

Gene Therapy vs Gene Editing: Gene therapy adds a functional gene; gene editing modifies the existing DNA sequence.
Somatic vs Germline Editing: Somatic editing affects only the treated individual; germline editing can be inherited and is ethically controversial.

RNA Interference (RNAi)

Mechanism and Therapeutic Applications

RNA interference (RNAi) is a natural process of post-transcriptional gene silencing, mediated by small RNA molecules such as miRNA and siRNA.

miRNA: Endogenous, regulates multiple genes by imperfect base pairing.
siRNA: Exogenous or endogenous, targets specific mRNA for degradation.
Applications: Used in cancer therapy to silence oncogenes and in pathway research.
Challenges: Delivery barriers, RNA instability, and toxicity limit clinical use.

Targeted Therapy

Mechanisms and Types

Targeted therapies are drugs designed to specifically inhibit molecular pathways critical for cancer cell survival and proliferation, reducing toxicity compared to traditional chemotherapy.

Monoclonal Antibodies: Target cell surface receptors (e.g., HER2 in breast cancer).
Small Molecule Inhibitors: Block intracellular signaling pathways.

Nanomedicine

Nanoparticle Drug Delivery

Nanomedicine uses nanoscale materials for drug delivery, improving targeting and reducing side effects.

Precision Targeting: Nanoparticles can be engineered to deliver drugs directly to diseased cells.

Introduction to Cancer

Foundations of Cancer Biology

Cancer is a genetic disease characterized by uncontrolled cell growth due to the accumulation of somatic mutations. It is considered an evolutionary process, as tumor cells undergo natural selection for traits that promote survival and proliferation.

Differences from Normal Cells: Uncontrolled proliferation, loss of regulation, altered microenvironment interactions.
Complex Tissues: Tumors consist of cancer cells and supporting stromal cells.

Evolutionary Progression of Cancer

Cancer develops through a multi-step process involving the accumulation of mutations and natural selection of the most aggressive cells.

Initiation: Somatic mutation occurs.
Progression: Additional mutations lead to uncontrolled growth.
Evasion: Tumor cells escape apoptosis and immune surveillance.
Growth & Dispersal: Angiogenesis and metastasis enable tumor expansion and spread.

Tumor Metabolism (Warburg Effect)

Cancer cells preferentially use aerobic glycolysis (Warburg effect), converting glucose to lactate even in the presence of oxygen. This supports rapid biosynthesis needed for proliferation, despite being less efficient for ATP production.

Normal Cells: Use oxidative phosphorylation (36 ATP per glucose).
Cancer Cells: Use aerobic glycolysis (2 ATP per glucose), favoring biomolecule production.

Tumor Types: Benign vs Malignant

Tumors are classified based on their behavior and clinical consequences.

Benign Tumors: Localized, resemble normal cells, may cause problems due to size or hormone secretion.
Malignant Tumors: Invasive, metastatic, continuously proliferating.

Angiogenesis

Angiogenesis is the formation of new blood vessels, which tumors require for oxygen, nutrients, and waste removal. Without angiogenesis, tumors cannot grow beyond a small size.

Breast Cancer Subtypes

Triple Positive Breast Cancer (ER+, PR+, HER2+)

Driven by: Estrogen, progesterone, and HER2 signaling.
Treatments: Hormone therapy (e.g., Tamoxifen), HER2-targeted therapy (e.g., Trastuzumab), chemotherapy.

Triple Negative Breast Cancer (TNBC; ER–, PR–, HER2–)

Lacks: Hormone and HER2 signaling; no targeted therapy options.
Clinical Implications: More aggressive, higher metastasis and recurrence rates, relies on chemotherapy.

Genetic Diseases and Cancer

Categories of Genetic Disorders

Autosomal Dominant: One mutated allele is sufficient (e.g., Huntington’s disease).
Autosomal Recessive: Two mutated alleles required (e.g., cystic fibrosis, sickle cell anemia).
X-Linked Disorders: Mutation on X chromosome; males more severely affected (e.g., Duchenne muscular dystrophy, hemophilia).
Complex (Multifactorial) Disorders: Involve multiple genes and environmental factors (e.g., diabetes, cardiovascular disease, cancer).
Mitochondrial Disorders: Inherited maternally; affect tissues with high energy demands.

Cancer as a Genetic Disease

Cancer arises from the accumulation of mutations in key genes, including tumor suppressors and oncogenes. Multiple mutations are required for tumor development, and the same cancer type can have different mutations in different patients.

Tumor Suppressors vs Oncogenes

Tumor Suppressor Genes: Inhibit cell growth; loss-of-function mutations promote cancer (e.g., TP53, BRCA1, APC).
Oncogenes: Promote cell growth; gain-of-function mutations promote cancer (e.g., KRAS, EGFR, PIK3CA).

Key Insight: Tumor suppressors act as "brakes"; oncogenes act as "accelerators" of cell proliferation.

Common Cancer Driver Genes

TP53: Most commonly mutated; controls DNA damage response.
KRAS: Regulates key signaling pathways; often mutated in pancreatic, lung, and colorectal cancers.
PIK3CA: Activates PI3K pathway; promotes cell survival and proliferation.

Cancer-Specific Mutation Patterns

Cancer Type	Common Mutated Genes
Lung	TP53, KRAS
Breast	BRCA1, TP53, PIK3CA
Colorectal	APC, KRAS, SMAD4, TP53
Pancreatic	KRAS, TP53, SMAD4
Hepatic	TP53, ARID1A/2

Key Cancer Pathways

Cell Cycle Control: TP53
Growth Signaling (MAPK, PI3K): KRAS, PIK3CA
DNA Repair: BRCA1, ATM
Wnt Signaling: APC

Genetic Heterogeneity

Tumors are genetically diverse, leading to variability in treatment response among patients with the same cancer type.

Clinical Applications (Precision Oncology)

Personalized Treatment: Therapy is tailored based on the patient's mutation profile.
Biomarker-Driven Therapy: Specific mutations guide drug selection (e.g., EGFR inhibitors for EGFR mutations, PARP inhibitors for BRCA1 mutations).

Key Cancer Genes: Functions and Clinical Relevance

Gene	Type	Function	Mutation Effect	Associated Cancers
TP53	Tumor Suppressor	DNA damage response, cell cycle arrest, apoptosis	Loss leads to unchecked division, genomic instability	Many (lung, breast, colorectal, etc.)
KRAS	Oncogene	MAPK signaling, growth signal transduction	Constitutive activation, uncontrolled proliferation	Pancreatic, lung, colorectal
BRCA1	Tumor Suppressor	DNA repair (double-strand breaks)	Increased mutation rate, genomic instability	Breast, ovarian
FGFR2	Oncogene	Growth factor receptor, RTK signaling	Increased signaling, proliferation	Breast, melanoma
APC	Tumor Suppressor	Wnt pathway regulation	Uncontrolled growth	Colorectal
SMAD4	Tumor Suppressor	TGF-β signaling, growth inhibition	Loss of inhibitory signaling	Pancreatic
PIK3CA	Oncogene	PI3K pathway activation	Increased survival, proliferation	Breast, colorectal, leukemia
HNF1A	Transcription Factor	Gene regulation, tissue-specific expression	Altered gene expression, differentiation	Liver
ARID2	Tumor Suppressor	Chromatin remodeling	Dysregulated gene expression	Hepatic

Summary Table: Inheritance Patterns of Genetic Disorders

Pattern	Key Features	Examples
Autosomal Dominant	One mutated allele sufficient; often structural/regulatory proteins	Huntington's disease
Autosomal Recessive	Two mutated alleles required; often enzyme deficiencies	Cystic fibrosis, sickle cell anemia
X-Linked	Mutation on X chromosome; males more affected	Duchenne muscular dystrophy, hemophilia
Mitochondrial	Maternally inherited; affects high-energy tissues	Leber's hereditary optic neuropathy
Complex (Multifactorial)	Multiple genes + environment; unpredictable	Diabetes, cardiovascular disease, cancer

Key Equations and Concepts

Hardy-Weinberg Equation (for population genetics):

ATP Yield in Metabolism:

Normal cells (oxidative phosphorylation): Cancer cells (aerobic glycolysis):

Additional info:

Some explanations and examples were expanded for clarity and completeness.
Tables were inferred and formatted for comparison and classification.